|
Q2 FY2027
As of Aug 29, 2026
|
Q1 FY2027
As of May 30, 2026
|
Q4 FY2026
As of Feb 28, 2026
|
Q3 FY2026
As of Nov 29, 2025
|
Q2 FY2026
As of Aug 30, 2025
|
Q1 FY2026
As of May 31, 2025
|
Q4 FY2025
As of Mar 1, 2025
|
Q3 FY2025
As of Nov 30, 2024
|
Q2 FY2025
As of Aug 31, 2024
|
Q1 FY2025
As of Jun 1, 2024
|
Q4 FY2024
As of Mar 2, 2024
|
Q3 FY2024
As of Nov 25, 2023
|
Q2 FY2024
As of Aug 26, 2023
|
Q1 FY2024
As of May 27, 2023
|
Q4 FY2023
As of Feb 25, 2023
|
Q3 FY2023
As of Nov 26, 2022
|
Q2 FY2023
As of Aug 27, 2022
|
Q1 FY2023
As of May 28, 2022
|
Q4 FY2022
As of Feb 26, 2022
|
Q3 FY2022
As of Nov 27, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Current assets | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Receivables, net | ||||||||||||||||||||
| Allowance for Credit Loss | ||||||||||||||||||||
| Inventories, net | ||||||||||||||||||||
| Contract assets | ||||||||||||||||||||
| Other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Property, plant and equipment, net | ||||||||||||||||||||
| Accumulated Depreciation Property, Plant, and Equipment | ||||||||||||||||||||
| Operating lease right-of-use assets | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Intangible assets, net | ||||||||||||||||||||
| Other non-current assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and Shareholders’ Equity | ||||||||||||||||||||
| Current liabilities | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued compensation and benefits | ||||||||||||||||||||
| Contract liabilities | ||||||||||||||||||||
| Operating lease liabilities | ||||||||||||||||||||
| Other current liabilities | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Long-term debt | ||||||||||||||||||||
| Non-current operating lease liabilities | ||||||||||||||||||||
| Non-current self-insurance reserves | ||||||||||||||||||||
| Other non-current liabilities | ||||||||||||||||||||
| Shareholders’ equity | ||||||||||||||||||||
| Junior preferred stock of $1.00 par value; authorized 200,000 shares; zero issued and outstanding | ||||||||||||||||||||
| Common stock of $0.33-1/3 par value; authorized 50,000,000 shares; issued and outstanding 20,893,469 and 21,220,350, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Total shareholders’ equity | ||||||||||||||||||||
| Total liabilities and shareholders’ equity | ||||||||||||||||||||
| Common Stock, Par or Stated Value Per Share | ||||||||||||||||||||
| Common Stock, Shares Authorized | ||||||||||||||||||||
| Common Stock, Shares, Issued | ||||||||||||||||||||
Loading...
